Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 3/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 3/20 | 0.36 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17189522 | 0.98 | SMN1; SMN2 (0.34) | PLA2G2APLA2G4APLA2G10KDM4EMEN1 | |
| SCHEMBL26539157 | 0.92 | SMN1; SMN2 (0.35) | PLA2G2APLA2G4APLA2G10KDM4EMEN1 | |
| SCHEMBL12158912 | 0.92 | PRKDC (0.31) | PLA2G2APLA2G4APLA2G10ALDH1A1PRKDC | |
| SCHEMBL15888796 | 0.90 | GPR3 (0.34) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL17248436 | 0.90 | CHEK2 (0.32) | KDM4EMEN1NPC1ALDH1A1MAPT | |
| SCHEMBL23737652 | 0.89 | ALOX5 (0.34) | PRKDC | |
| SCHEMBL17248449 | 0.89 | ALOX5 (0.43) | PLA2G2APLA2G4APLA2G10PRKDC | |
| SCHEMBL25051209 | 0.89 | PRKDC (0.32) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL17248386 | 0.88 | PLA2G2A (0.34) | PLA2G2APLA2G4APLA2G10PRKDC | |
| SCHEMBL15888851 | 0.88 | PTPN1 (0.31) | PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10361378-B2 | Organic electroluminescent device | NIPPON STEEL CHEMICAL & MATERIAL CO., LTD. (JP) | 2019-07-23 | — | — | US | disclosed |
| US-20150325796-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | NIPPON STEEL CHEMICAL & MATERIAL CO., LTD. (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20150325796-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | NIPPON STEEL CHEMICAL & MATERIAL CO., LTD. (JP) | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10361378-B2 | Organic electroluminescent device | ELF3, DDT, LEF1 | PLA2G2A 4329/4885PLA2G4A 4258/4885PLA2G10 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.